Literature DB >> 12618029

Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3.

Bogdan I Florea1, Maria L Cassara, Hans E Junginger, Gerrit Borchard.   

Abstract

Pulmonary drug delivery serves two purposes, namely the application of locally active compounds for treatment of diseases afflicting the lung, and the utilization of the pulmonary epithelia as absorption sites for macromolecular drugs. To elucidate the mechanisms involved in the pulmonary absorption and metabolism of compounds on a cellular level, cell culture models have shown to be, though limited, rather useful in predicting in vivo conditions. The Calu-3 cell line has been employed recently as a model for the airway epithelium in a number of drug transport and metabolism studies. The results of these studies, as well as an evaluation of the predictive potency of the model, are presented here. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12618029     DOI: 10.1016/s0168-3659(02)00356-5

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  28 in total

1.  Metabolic cleavage of cell-penetrating peptides in contact with epithelial models: human calcitonin (hCT)-derived peptides, Tat(47-57) and penetratin(43-58).

Authors:  Rachel Tréhin; Hanne M Nielsen; Heinz-Georg Jahnke; Ulrike Krauss; Annette G Beck-Sickinger; Hans P Merkle
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

2.  Cellular uptake but low permeation of human calcitonin-derived cell penetrating peptides and Tat(47-57) through well-differentiated epithelial models.

Authors:  Rachel Tréhin; Ulrike Krauss; Annette G Beck-Sickinger; Hans P Merkle; Hanne M Nielsen
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

3.  hPEPT1 is responsible for uptake and transport of Gly-Sar in the human bronchial airway epithelial cell-line Calu-3.

Authors:  Helle Bach Søndergaard; Birger Brodin; Carsten Uhd Nielsen
Journal:  Pflugers Arch       Date:  2007-12-20       Impact factor: 3.657

4.  The 2009 pandemic H1N1 and triple-reassortant swine H1N1 influenza viruses replicate efficiently but elicit an attenuated inflammatory response in polarized human bronchial epithelial cells.

Authors:  Hui Zeng; Claudia Pappas; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

5.  Biomimetics of the pulmonary environment in vitro: A microfluidics perspective.

Authors:  Janna Tenenbaum-Katan; Arbel Artzy-Schnirman; Rami Fishler; Netanel Korin; Josué Sznitman
Journal:  Biomicrofluidics       Date:  2018-05-29       Impact factor: 2.800

6.  Metabolic cleavage and translocation efficiency of selected cell penetrating peptides: a comparative study with epithelial cell cultures.

Authors:  Christina Foerg; Kathrin M Weller; Helene Rechsteiner; Hanne M Nielsen; Jimena Fernández-Carneado; René Brunisholz; Ernest Giralt; Hans P Merkle
Journal:  AAPS J       Date:  2008-06-28       Impact factor: 4.009

7.  Formulation and evaluation of carrier-free dry powder inhaler containing sildenafil.

Authors:  Thi-Tram Nguyen; Eun-Jin Yi; Kyu-Mok Hwang; Cheol-Hee Cho; Chun-Woong Park; Ju-Young Kim; Yun-Seok Rhee; Eun-Seok Park
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

8.  Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3).

Authors:  Durga Kalyani Paturi; Deep Kwatra; Hari Krishna Ananthula; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2009-09-25       Impact factor: 5.875

9.  Cultured human airway epithelial cells (calu-3): a model of human respiratory function, structure, and inflammatory responses.

Authors:  Yan Zhu; Aaron Chidekel; Thomas H Shaffer
Journal:  Crit Care Res Pract       Date:  2010-06-27

10.  Functional and cytometric examination of different human lung epithelial cell types as drug transport barriers.

Authors:  Kyoung Ah Min; Gus R Rosania; Chong-Kook Kim; Meong Cheol Shin
Journal:  Arch Pharm Res       Date:  2016-01-08       Impact factor: 4.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.